Intensive Viral Dynamics Substudy of A5248

Completed

Conditions studied: HIV Infections, Treatment Naive

In brief

The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The main study will estimate the viral load decay rate in treatment-naive HIV-infected participants receiving RAL and emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). This substudy of A5248 will similarly examine the characteristics of decrease in viral load but will focus on estimating the time at which first-phase viral decay starts, following initiation of the study drugs.

Key facts

Study ID

NCT00852618

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

11

Starts

2008-05-01

Expected to finish

2008-09-01

Last updated by the study team

2021-11-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrollment in A5248
• Willing and able to provide informed consent

Where it is running

• University of Colorado Hospital CRS — Aurora, Colorado, United States
• IHV Baltimore Treatment CRS — Baltimore, Maryland, United States
• Johns Hopkins University CRS — Baltimore, Maryland, United States
• Brigham and Women's Hospital Therapeutics Clinical Research Site (BWH TCRS) CRS — Boston, Massachusetts, United States
• Trillium Health ACTG CRS — Rochester, New York, United States
• Vanderbilt Therapeutics (VT) CRS — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.